Difference between revisions of "Team:BGU Israel/test/Collaborations"
| Line 1: | Line 1: | ||
{{BGU_Israel}} | {{BGU_Israel}} | ||
| + | <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> | ||
| + | <html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr"> | ||
| − | < | + | <head> |
| − | + | ||
| − | + | <!-- Scripts --> | |
| + | <script src="http://igembgu.com/wiki/JS/TUM13_jquery-1.10.2.js?action=raw&ctype=text/javascript" type="text/javascript"></script> | ||
| + | <script src="http://igembgu.com/wiki/JS/TUM13_slimbox2.js?action=raw&ctype=text/javascript" type="text/javascript"></script> | ||
| + | <script src="http://igembgu.com/wiki/JS/TUM13_bxslider.js?action=raw&ctype=text/javascript" type="text/javascript"></script> | ||
| + | <script src="http://igembgu.com/wiki/JS/TUM13_Script?action=raw&ctype=text/javascript" type="text/javascript"></script> | ||
| + | <script src="http://igembgu.com/wiki/JS/TUM13_history.js?action=raw&ctype=text/javascript" type="text/javascript"></script> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| + | <!-- Stylesheets --> | ||
| + | <link href="http://igembgu.com/wiki/css/TUM13_normalize.css" type="text/css" rel="stylesheet"> | ||
| + | <link href="http://igembgu.com/wiki/css/UM13_reset.css" type="text/css" rel="stylesheet"> | ||
| + | <link href="http://igembgu.com/wiki/css/TUM13_slimbox2.css" type="text/css" rel="stylesheet"> | ||
| + | <link href="http://igembgu.com/wiki/css/TUM13_normalize.css" type="text/css" rel="stylesheet"> | ||
| + | <link href="http://igembgu.com/wiki/css/TUM13_bxslider.css" type="text/css" rel="stylesheet"> | ||
| + | <link href="http://igembgu.com/wiki/css/TUM13_wiki.css" type="text/css" rel="stylesheet"> | ||
| − | + | </head> | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | </head> | + | |
| Line 29: | Line 28: | ||
| − | + | <body class="mediawiki ltr ns-0 ns-subject page-Team_BGU_Israel"> | |
| − | + | <div id="Div1"> | |
| − | + | <img src="https://static.igem.org/mediawiki/2015/8/8f/2015igembanner.jpg" height="150px" width="100%"> | |
| − | + | <a name="top" id="A1"></a> | |
| − | + | <h1 class="firstHeading">Team:BGU Israel</h1> | |
| − | + | <div id="Div2"> | |
| − | + | <div id="contentSub"></div> | |
| − | + | <!-- start content --> | |
| − | + | <p> | |
| − | <div id="header-container"> | + | <div id="header-container"> |
| − | + | <div id="header"> | |
| − | + | <table style="background-color:transparent "> | |
| − | + | <tr> | |
| − | + | <td style="width:200px"></td> | |
| − | + | <td> <img src="https://static.igem.org/mediawiki/2015/8/83/Igem_bgu_logo.png" height="120px" width="490px"><td> | |
| − | + | <td></td> | |
| − | + | </tr> | |
| − | + | </table> | |
| − | + | </div> | |
| − | + | <!-- | |
| − | + | <a href="https://2015.igem.org/Main_Page"><img id="igem-logo" src="https://static.igem.org/mediawiki/2013/9/9c/TUM13_igem-logo.png" /></a> | |
| − | + | <a href="http://www.tum.de/en/homepage/"><img id="tum-logo" src="https://static.igem.org/mediawiki/2013/9/9b/TUM13_tum-logo.png" /></a> | |
| − | + | <a href="https://2013.igem.org/Team:TU-Munich"><img id="physco-logo" src="https://static.igem.org/mediawiki/2013/c/c4/TUM13_physco-logo-klein.png" /></a> | |
| − | + | </div> | |
| − | + | <!-- Start of menu --> | |
| − | + | <div id="menu"> | |
| − | + | <ul> | |
| − | + | <li><a id="home" href="https://2015.igem.org/Team:BGU_Israel">Home</a></li> | |
| − | + | <li><a id="A2" href="https://2015.igem.org/Team:BGU_Israel/Team">Team</a> | |
| − | + | <!--<ul> optional | |
| − | + | <li><a href="https://2013.igem.org/Team:BGU_Israel/Team/Members">Members</a></li> | |
| − | + | <li><a href="https://2013.igem.org/Team:BGU_Israel/Team/Sponsors">Sponsors</a></li> | |
| − | + | <li><a href="https://2013.igem.org/Team:BGU_Israel/Team/Collaborations">Collaborations</a></li> | |
| − | + | <li><a href="https://2013.igem.org/Team:BGU_Israel/Team/Gallery">Pictures</a></li> | |
| − | + | <li><a href="https://2013.igem.org/Team:BGU_Israel/Team/Statistics">Timeline</a></li> | |
| − | + | <li><a href="https://2013.igem.org/Team:BGU_Israel/Team/Attributions">Attributions</a></li> | |
| − | + | <li><a href="https://2013.igem.org/Team:BGU_Israel/Team/Judging">Judging</a></li> | |
| − | + | </ul> --> | |
| − | + | </li> | |
| − | + | <li>Project | |
| − | + | <ul> | |
| − | + | <li><a id="A3" href="https://2015.igem.org/Team:BGU_Israel/Description">Description</a></li> | |
| − | + | <li> <a href="https://2015.igem.org/Team:BGU_Israel/Experiments">Experiments & Protocols</a> </li> | |
| − | + | <li><a href="https://2015.igem.org/Team:BGU_IsraelResults">Results</></a> </li> | |
| − | + | <li><a href="https://2015.igem.org/Team:BGU_Israel/Design">Design</a></li> | |
| − | + | </ul> | |
| − | + | </li> | |
| − | + | <li>Parts | |
| − | + | <ul> | |
| − | + | <li><a href="https://2015.igem.org/Team:BGU_Israel/Parts">Team Parts</a></li> | |
| − | + | <li><a href="https://2015.igem.org/Team:BGU_Israel/Basic_Part">Basic Parts</a> </li> | |
| − | + | <li><a href="https://2015.igem.org/Team:BGU_Israel/Composite_Part">Composite Parts</a></li> | |
| − | + | <li><a href="https://2015.igem.org/Team:BGU_Israel/Part_Collection">Part Collection</a> </li> | |
| − | + | </ul> | |
| − | + | </li> | |
| − | + | <li><a id="A4" href="https://2015.igem.org/Team:BGU_Israel/Notebook">Notebook</a></li> | |
| − | + | <li> MORE | |
| − | + | <ul> | |
| − | + | <li><a href="https://2015.igem.org/Team:BGU_Israel/Attributions">Attributions</a></li> | |
| − | + | <li> <a href="https://2015.igem.org/Team:BGU_Israel/Collaborations">Collaborations</a></li> | |
| − | + | <li> <a href="https://2015.igem.org/Team:BGU_Israel/Practices">Human practices</a></li> | |
| − | + | <li> <a href="https://2015.igem.org/Team:BGU_Israel/Safety">Safety</a></li> | |
| − | + | <li> <a href="https://2015.igem.org/Team:BGU_Israel/Modeling">Modeling</a></li> | |
| − | + | <!-- <li> <a href="https://2015.igem.org/Team:BGU_Israel/Measurement">MEASUREMENT</a></li> | |
| − | + | <!-- <a href="https://2015.igem.org/Team:BGU_Israel/Software"><li>SOFTWARE</li></a> --> | |
| − | + | <li> <a href="https://2015.igem.org/Team:BGU_Israel/Entrepreneurship">Entrepreneurship</a></li> | |
| − | + | </ul> | |
| − | + | </li> | |
| + | |||
| + | </ul> | ||
| + | </div> | ||
| + | <!-- End of menu --> | ||
| − | |||
</div> | </div> | ||
| − | |||
| − | + | <div id="wikicontent-container"> | |
| − | + | <div id="wikicontent"> | |
| − | <div id="wikicontent-container"> | + | |
| − | + | ||
| − | + | <br /><br /> | |
| − | + | <h2>Collaboration</h2><br /> | |
| − | + | <p>We have collaborated with a couple of iGEM teams this year:</p> <br/> | |
| − | + | <ul> | |
| − | + | <li><a href="https://2015.igem.org/Team:BGU_Israel/Collaborations/#Stockholm">Scientific collaborations -Stockholm</a> </li> | |
| − | + | <li><a href="https://2015.igem.org/Team:BGU_Israel/Collaborations/#">Written articles for the Amoy newsletter</a></li> | |
| − | + | <li><a href="https://2015.igem.org/Team:BGU_Israel/Collaborations/#">Collaboration on human practice survey</a></li> | |
| − | + | <li><a href="https://2015.igem.org/Team:BGU_Israel/Collaborations/#">Attended "Mini jamboree" conference hosted by the "Technion"</a></li> | |
| − | + | </ul> | |
| − | + | ||
| − | + | ||
| − | + | <a name="Stockholm"></a> | |
| − | + | <h4>Introduction</h4><br /> | |
| − | + | <p><a href="https://2015.igem.org/Team:Stockholm"> Stockholm team </a>is working on cancer diagnosis by engineering of a bacterial sensor which could detect trace amounts of cancer biomarkers.</p> | |
| + | <br/> | ||
| − | + | <table> | |
| − | + | <tr> | |
| − | + | <td> | |
| − | + | <h5>Stockholm Abstract:</h5><br/> | |
| − | + | <p>"Synthetic biology offers many potential cost-effective healthcare technologies. One of those could be new ways to diagnose and treat disease at an early stage. Current techniques for biomarker detection (e.g. ELISA, RIA) are time consuming, expensive and require specialised equipment.</p> | |
| − | + | <p>We intend to design a microbiological system for the detection of low quantities of biomarkers. This assay aims to be easier and more cost efficient than existing techniques and possible to perform in modestly equipped settings. Initially, we will focus on the expression of a receptor for the desired biomarker. Depending on the nature of the biomarker, the receptor will be either be native or designed. </p> | |
| − | + | <p>Upon biomarker detection, signal amplification will be triggered by our receptor system to activate a read out/detection system (e.g. Luciferase, GFP) inside the microorganism to artificially amplify the extracellular signal. In the next stage, the team will go on to design a read-out system to measure the concentration of biomarkers in body samples. Finally we want to investigate if we can make this system transferable to other biomarkers, changing only the receptor part of the system. </p> | |
| − | + | <p>The system would be cheap, fast and possible to distribute without advanced equipment. Our motivation is to improve patient prognosis and quality of life and to improve efficiency and reduce costs within the healthcare system." </p> | |
| − | + | </td> | |
| − | + | </tr> | |
| − | + | </table> | |
| − | + | <br/> | |
| − | + | <p>Our assistance to the team is to express an GPI-anchored Affibody <a href="">[biobrick number??+link]</a> on the plasma membrane of human cancer cells, which can then be specifically targeted by a compatible drug or toxin (Fig. 1). | |
| − | + | </p><br/> | |
| − | + | <div align="center"><img src="https://static.igem.org/mediawiki/2015/4/47/BGU_Sstockholm_Collaboration.PNG" width="700px" height="400" /><br/> | |
| − | + | Fig. 1. Possible applications of Affibody expression in cancer cells.</div> | |
| − | + | <br/><br/> | |
| − | + | <h4>Results</h4><br/> | |
| − | + | <h5>1. Cloning</h5><br/> | |
| − | + | <p>We cloned the Affibody <a href="">[biobrick number??+link]</a> into our AAV vector for expression under CMV promoter (Fig. 2). | |
| − | + | </p> | |
| − | + | <table style="background-color:transparent "> | |
| − | + | <tr> | |
| − | + | <td width="80%" style="border-style: hidden;"><div align="center"><b>A</b></div></td> | |
| − | + | <td width="20%" style="border-style: hidden;"><div align="center"><b>B</b></div></td> | |
| − | + | </tr> | |
| − | + | <tr> | |
| − | + | <td width="80%" style="border-style: hidden;"><img src="https://static.igem.org/mediawiki/2015/b/bd/Collaboration_cloning_result1.png" height="500px" width="600px"/></td> | |
| − | + | <td width="20%" style="border-style: hidden;"><a href="https://static.igem.org/mediawiki/2015/3/37/Collaboration_cloning_result2.png" target="blank"><img src="https://static.igem.org/mediawiki/2015/3/37/Collaboration_cloning_result2.png" height="200px" width="150px"/></a></td> | |
| − | + | </tr> | |
| − | + | </table> | |
| − | + | <br/> Fig. 2. A. Cloning map of Affibody into AAV vector. B. Successful cloning results. | |
| − | + | <h5> 2. Affibody expression in human cancer cells</h5><br/> | |
| − | + | Affibody-AAV was produced [link to protocol of virus production], and used for transduction of human cancer cell line (HT1080 fibrosarcoma cell line].<br/> | |
| − | + | As the Affibody was predesigned to include 3xFLAG peptide (DYKDDDDK) in its sequence, we used anti-FLAG-specific primary antibody to specifically detect the protein using immunofluorescence. | |
| − | + | <br/> <br/> | |
| − | + | <h4>Results</h4> | |
| − | + | <h4>Conclusion and future aspects</h4> | |
| − | + | <p>Affibody construct could be successfully expressed in human cancer cells on cell membrane. | |
| − | + | In the future, the Affibody could be expressed exclusively in cancer cells using our Boomerang approach using dCas9-VP64-gRNA system under the control of cancer-specific promoters. | |
| − | + | </p> | |
| − | + | ||
| − | + | <br/> <br/> | |
| + | <h2>Polices & Practices collaborations:</h2> | ||
| + | |||
| + | <a name="France"></a> | ||
| + | <h5>France-Aix-Maseille, Questioner</h5> | ||
| + | |||
| + | <p>Aix-Marseille Université (France), propose a collaboration. They needed to collect a lot of information about chewing-gum and GMOs around the world. | ||
| + | They prepared a small survey, and we went to the country streets and interviewed random people. | ||
| + | It was a fun challenge. We received a gold badge for our help. </p> | ||
| + | <div align="center"> | ||
| + | <table> | ||
| + | <tr> | ||
| + | <td> | ||
| + | <h5>Aix-Marseille project idea:</h5><br/> | ||
| + | <p>"Nowadays, chewing gum is the second urban pollutant after cigarette butts. To clean chewing gum, specific engines are used but they are heavy and expensive. The time required for its use is long and they need a large quantity of water. Besides economical aspects, chewing gums have an environmental impact. They are dangerous for the wildlife such as birds. Indeed, believing that it is bread, they eat chewing gums and choke. Regarding these alarming facts, we have decided to create a new environmentally- responsible way to sanitize our streets." </p> | ||
| + | </td> | ||
| + | <td></td> | ||
| + | </tr> | ||
| + | </table> | ||
| + | </div> | ||
| + | |||
| − | + | <a name="Amoy"></a> | |
| + | <h5>China-Amoy university, article</h5> | ||
| + | <p>Amoy iGEM team issued monthly newsletter that enabled igem teams from all over the world to share information about their project and discuss issues concerning it and synthetic biology in general. | ||
| + | For this year’s version of the Newsletter iGEM Amoy contacted iGEM Ben-Gurion to include us in the 2015 issue. We had the honor to collaborate and publish an article about our project in the fifth issue of 2015 Newsletter. We described our project and an update on our progress.</p> | ||
| + | <a href="">link to our article from their site</a> <br/> | ||
| + | |||
| + | <a name="Technion"></a> | ||
| + | <h5>Israel-Technion, Mini Jamboree</h5> <p>[tbd] </p> | ||
| + | |||
| − | < | + | <!-- Finish HERE --> |
| − | + | ||
| − | + | ||
| + | </div> | ||
| − | <div | + | </div> |
| − | < | + | </div> |
| + | </div> | ||
| + | <div id="social-footer"> | ||
| + | <a id="gotop" href="#"></a> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| + | <div id="follow"> | ||
| + | <h2>Follow us:</h2> | ||
| + | <div> | ||
| + | <a id="adress" href="http://igembgu2015hp.wix.com/boomerang" target="blank"></a> | ||
| + | <a id="mail" href="mailto:igembgu2015@gmail.com "></a> | ||
| + | <a id="facebook" href="https://www.facebook.com/iGEMBGU" target="blank"></a> | ||
| + | <a id="twitter" href="https://twitter.com/BGU_iGEM" target="blank"></a> | ||
| + | <a id="youtube" href="http://player.vimeo.com/video/110058399" target="blank"></a> | ||
| + | </div> | ||
| + | </div> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | </div> | + | |
| + | <div id="Div3"> | ||
| + | <h2>Address:</h2> | ||
| + | <p> <br /> | ||
| + | <p> <br /> | ||
| + | |||
| + | </div> | ||
| + | |||
| + | </div> | ||
| Line 230: | Line 262: | ||
| − | <!-- Saved in parser cache with key 2013_igem_org:pcache:idhash:107-0!1!0!!en!2!edit=0 and timestamp 20150808061127 --> | + | <!-- Saved in parser cache with key 2013_igem_org:pcache:idhash:107-0!1!0!!en!2!edit=0 and timestamp 20150808061127 --> |
| − | <div class="printfooter"></div> | + | <div class="printfooter"></div> |
| − | + | <div id="catlinks"><div id='Div4' class='catlinks catlinks-allhidden'></div></div> <!-- end content --> | |
| − | + | <div class="visualClear"></div> | |
| − | <!-- PAGE FOOTER -- ITEMS FROM COLUMN ! HAVE BEEN MOVED HERE -- RDR --> | + | <!-- PAGE FOOTER -- ITEMS FROM COLUMN ! HAVE BEEN MOVED HERE -- RDR --> |
| − | <div class="visualClear"></div> | + | <div class="visualClear"></div> |
| − | + | <div id='footer-box' class='noprint'> | |
| − | + | <div id="footer"> | |
| − | + | <div id="f-copyrightico"><a href="http://creativecommons.org/licenses/by/3.0/"><img src="http://i.creativecommons.org/l/by/3.0/88x31.png" alt="Attribution 3.0 Unported" width="88" height="31" /></a></div> | |
| − | + | <ul id="f-list"> | |
| − | + | <!-- Recentchanges is not handles well DEBUG --> | |
| − | + | </ul> | |
| − | + | </div> <!-- close footer --> | |
| − | + | </div> <!-- close footer-box --> | |
| − | <script> if (window.runOnloadHook) runOnloadHook();</script> | + | <script> if (window.runOnloadHook) runOnloadHook();</script> |
| − | <!-- Served in 0.149 secs. --></body> | + | <!-- Served in 0.149 secs. --></body> |
| − | <!-- Saved in parser cache with key 2015_igem_org:pcache:idhash:1062-0!1!0!!en!2!edit=0 and timestamp 20150823083101 --> | + | <!-- Saved in parser cache with key 2015_igem_org:pcache:idhash:1062-0!1!0!!en!2!edit=0 and timestamp 20150823083101 --> |
| − | <div class="printfooter"> | + | <div class="printfooter"> |
| − | Retrieved from "<a href="https://2015.igem.org/Team:BGU_Israel/Team">https://2015.igem.org/Team:BGU_Israel/Team</a>"</div> | + | Retrieved from "<a href="https://2015.igem.org/Team:BGU_Israel/Team">https://2015.igem.org/Team:BGU_Israel/Team</a>"</div> |
| − | + | <div class="visualClear"></div> | |
| − | <!-- PAGE FOOTER -- ITEMS FROM COLUMN ! HAVE BEEN MOVED HERE -- RDR --> | + | <!-- PAGE FOOTER -- ITEMS FROM COLUMN ! HAVE BEEN MOVED HERE -- RDR --> |
| − | <div class="visualClear"></div> | + | <div class="visualClear"></div> |
| − | <script> if (window.runOnloadHook) runOnloadHook();</script> | + | <script> if (window.runOnloadHook) runOnloadHook();</script> |
| − | </html> | + | </html> |
Revision as of 11:03, 10 September 2015
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
Team:BGU Israel
Collaboration
We have collaborated with a couple of iGEM teams this year:
- Scientific collaborations -Stockholm
- Written articles for the Amoy newsletter
- Collaboration on human practice survey
- Attended "Mini jamboree" conference hosted by the "Technion"
Introduction
Stockholm team is working on cancer diagnosis by engineering of a bacterial sensor which could detect trace amounts of cancer biomarkers.
Stockholm Abstract:
"Synthetic biology offers many potential cost-effective healthcare technologies. One of those could be new ways to diagnose and treat disease at an early stage. Current techniques for biomarker detection (e.g. ELISA, RIA) are time consuming, expensive and require specialised equipment.
We intend to design a microbiological system for the detection of low quantities of biomarkers. This assay aims to be easier and more cost efficient than existing techniques and possible to perform in modestly equipped settings. Initially, we will focus on the expression of a receptor for the desired biomarker. Depending on the nature of the biomarker, the receptor will be either be native or designed.
Upon biomarker detection, signal amplification will be triggered by our receptor system to activate a read out/detection system (e.g. Luciferase, GFP) inside the microorganism to artificially amplify the extracellular signal. In the next stage, the team will go on to design a read-out system to measure the concentration of biomarkers in body samples. Finally we want to investigate if we can make this system transferable to other biomarkers, changing only the receptor part of the system.
The system would be cheap, fast and possible to distribute without advanced equipment. Our motivation is to improve patient prognosis and quality of life and to improve efficiency and reduce costs within the healthcare system."
Our assistance to the team is to express an GPI-anchored Affibody [biobrick number??+link] on the plasma membrane of human cancer cells, which can then be specifically targeted by a compatible drug or toxin (Fig. 1).
Fig. 1. Possible applications of Affibody expression in cancer cells.
Results
1. Cloning
We cloned the Affibody [biobrick number??+link] into our AAV vector for expression under CMV promoter (Fig. 2).
Fig. 2. A. Cloning map of Affibody into AAV vector. B. Successful cloning results.
2. Affibody expression in human cancer cells
Affibody-AAV was produced [link to protocol of virus production], and used for transduction of human cancer cell line (HT1080 fibrosarcoma cell line].
As the Affibody was predesigned to include 3xFLAG peptide (DYKDDDDK) in its sequence, we used anti-FLAG-specific primary antibody to specifically detect the protein using immunofluorescence.
Results
Conclusion and future aspects
Affibody construct could be successfully expressed in human cancer cells on cell membrane.
In the future, the Affibody could be expressed exclusively in cancer cells using our Boomerang approach using dCas9-VP64-gRNA system under the control of cancer-specific promoters.
Polices & Practices collaborations:
France-Aix-Maseille, Questioner
Aix-Marseille Université (France), propose a collaboration. They needed to collect a lot of information about chewing-gum and GMOs around the world.
They prepared a small survey, and we went to the country streets and interviewed random people.
It was a fun challenge. We received a gold badge for our help.
Aix-Marseille project idea:
"Nowadays, chewing gum is the second urban pollutant after cigarette butts. To clean chewing gum, specific engines are used but they are heavy and expensive. The time required for its use is long and they need a large quantity of water. Besides economical aspects, chewing gums have an environmental impact. They are dangerous for the wildlife such as birds. Indeed, believing that it is bread, they eat chewing gums and choke. Regarding these alarming facts, we have decided to create a new environmentally- responsible way to sanitize our streets."
China-Amoy university, article
Amoy iGEM team issued monthly newsletter that enabled igem teams from all over the world to share information about their project and discuss issues concerning it and synthetic biology in general.
For this year’s version of the Newsletter iGEM Amoy contacted iGEM Ben-Gurion to include us in the 2015 issue. We had the honor to collaborate and publish an article about our project in the fifth issue of 2015 Newsletter. We described our project and an update on our progress.
link to our article from their site
Israel-Technion, Mini Jamboree
[tbd]
Follow us:
Address: